Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study

S. Adams, S. Loi, D. Toppmeyer, D. W. Cescon, M. De Laurentiis, R. Nanda, E. P. Winer, H. Mukai, K. Tamura, A. Armstrong, M. C. Liu, H. Iwata, L. Ryvo, P. Wimberger, H. S. Rugo, A. R. Tan, L. Jia, Y. Ding, V. Karantza, P. Schmid

Research output: Contribution to journal › Article › peer-review

157 Scopus citations

Fingerprint

Dive into the research topics of 'Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study'. Together they form a unique fingerprint.

Medicine & Life Sciences